Close Menu

NEW YORK (GenomeWeb) – With the long-awaited results from the TAILORx trial now public, Genomic Health is shifting attention and resources back to its core breast cancer test in an attempt to capitalize on a wave of public attention and take advantage of new openings the study has made into international markets.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.